Navigation Links
Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
Date:8/26/2011

RIDGEFIELD, Conn., Aug. 26, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN™, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.(1) The 12-week study will compare three doses of dabigatran etexilate (150mg bid, 220mg bid and 300mg bid) to warfarin in patients with both aortic valve replacements and mitral valve replacements.(1) A RE-ALIGN extension study will evaluate the ongoing safety of dabigatran etexilate in this patient population for up to 84 months.(1)

Mechanical heart valves are used to treat heart valve disease, which occurs when one or more valves in the heart does not function properly.(2) An estimated 2.5 percent of the American population has heart valve disease.(3) Approximately 100,000 patients undergo heart valve replacement in the U.S. each year,(4) 55 percent of which are mechanical heart valves.(5) Patients with mechanical heart valves require lifelong anticoagulation to help prevent blood clots from forming on or around the valve.(6) A meta-analysis of 46 studies involving patients with mechanical heart valves found the annual incidence of thromboembolism for those who are untreated to be 8.6 percent.(7)

"Boehringer Ingelheim is committed to ongoing research that will expand our understanding of dabigatran etexilate as a treatment option for patients with a variety of cardiovascular and thromboembolic conditions," said John Smith, MD, PhD, senior vice president for clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We are proud to announce the launch of RE-ALIGN and plans for a RE-ALIGN extension study, to assess dabigatran etexilate as a potential treatment option to reduce stroke risk in patients with mechanical heart valves."

Dabigatran etexilate was approved by the FDA in October 2010 as the first oral anticoagulant in more
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim and Ashokas Changemakers Launch "Making More Health" Competition
2. Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health"
3. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
4. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
5. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
6. Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
7. Boehringer Ingelheim to Purchase Amgens Fremont (USA) Facility
8. Boehringer Ingelheim to Purchase Amgens Fremont (California) Facility
9. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
10. Boehringer Ingelheim Initiates Phase III Clinical Trial With Afatinib in Advanced Breast Cancer
11. Boehringer Ingelheims Pradaxa Available in U.S. Pharmacies Starting Wednesday, November 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... , July 13, 2014  Eli Lilly and ... results from its non-clinical study in genetically engineered ... of the beta-amyloid antibody N3pG and beta-secretase inhibitor ... was more effective in removing clumps of amyloid-beta ... is thought to lead to Alzheimer,s disease (AD) ...
(Date:7/11/2014)... 11, 2014 The consumer marketing playbook ... industry sectors to better identify winning tools and ... engage with and understand consumers, as new technologies ... critical purchasing decisions. According to ... one area where organizations can observe a deep ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
... Israel, November 12 Surgeons,at the University of ... can be converted to an endovascular simulator,(ANGIO Mentor(TM), ... agreed" that the simulation improved the operative flow,increased ... operative and fluoroscopy time and the amount of ...
... New Data Suggesting Need for Improved ... Annual Meeting -, EXTON, Pa., Nov. 12 ViroPharma ... from its ongoing,open-label study, showing that in this study Cinryze(TM) ... (HAE),attacks seen in the study through the date of analysis. ...
Cached Medicine Technology:Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 3ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 4ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 5ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 6
(Date:7/13/2014)... 2014 Recently, 2014QuinceaneraDresses.com, the distinguished ... its new range of gorgeous Quinceanera dresses ... demand for elegant Quinceanera outfits is huge. Therefore, ... All the company’s newly released dresses are made ... all elegant and vivid. , It is ...
(Date:7/13/2014)... 2014 Epidemiologists forecast an increase in ... from 8,062 diagnosed incident cases in 2013 to 11,568 ... Rate (AGR) of 4.35%, during the forecast period. In ... diagnosed incident cases of aGVHD in the 6MM, with ... lowest number of diagnosed incident cases of aGVHD, with ...
(Date:7/13/2014)... July 13, 2014 Wright & Schulte ... has been scheduled in July of 2015, in U.S. ... lawsuits are in the discovery process in the ... Gergel is presiding over the multidistrict litigation (MDL). The ... behalf of individuals who allege that they took the ...
(Date:7/13/2014)... Palatine, Illinois (PRWEB) July 13, 2014 Hope ... facilitating a monthly grief support group at the Tamarack Senior ... will be held at 10:30 A.M. on the 3rd Wednesdays ... July 16th, 2014 at the Tamarack Community located at 55 ... to all bereaved individuals and there is no cost for ...
(Date:7/13/2014)... Recently, iFitDress.com, one of the most popular suppliers ... added a new selection of beautiful evening dresses ... a promotion for these evening gowns. Now, everybody can ... providing thousands of graceful gowns in its online store. ... France, Italy and many other countries. They are highly ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2
... have only recently begun to speculate that whats referred to ... genome that doesnt encode for proteins and previously seemed to ... for an important reason. ,But it wasnt ... of California, San Diego (UCSD) School of Medicine have discovered ...
... counters concerns of health care providers reluctant to invest in ... be published in the July issue of the Journal of ... medical center recouped its investment in electronic health records within ... medical records in New Orleans after Hurricane Katrina is one ...
... not to board a transatlantic flight with a potentially deadly ... and two Czechs who flew with him, media said ... scare two months ago when he flew to Montreal via ... Disease Control (CDC) had said he was infected with a ...
... Medicine have found that a newly available monoclonal antibody ... cells. ,In a study, the monoclonal ... and survival in human and mouse hepotocellular cancer (HCC) ... the new findings have significant implications not only for ...
... study conducted by University of Alberta and McGill University indicate ... depression. The rate of women is much higher compared ... recently in the European Journal of Cardiovascular Nursing. ,486 ... per cent of the women had worsening depression one year ...
... air pollution stats provided by the Ontario health department is ... deaths and 6,000 hospital admissions in Toronto each year, Dr. ... of the air quality health index. , The politicians ... a new plan to control air pollution. A new tool ...
Cached Medicine News:Health News:The Importance of Junk DNA 2Health News:Electronic Medical Records can Pay You Within 16 Months 2Health News:US TB Traveler Sued Over 'reckless and Selfish Behavior' 2Health News:Monoclonal Antibody Induces Death in Liver Cancer Cells 2Health News:Female Heart Attack Victims Show Signs of Lasting Depression 2
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Elisa strip reader...
Iems Incubator/Shaker expansion module for 2 module incubator/shaker. high performance microplate incubator and orbital shaker. It's superior temperature control and efficient orbital shaking reduce ...
... Millennium 2000 is a unique microprocessor controlled ... microplates in either 96 or 384 well ... via the control panel and all are ... visible under the clear protective cover. The ...
Medicine Products: